Avenue Therapeutics, INC.: directors' dealings · United States · SEC (Form 4)

About Avenue Therapeutics, INC.

Avenue Therapeutics, Inc. (ticker ATXI) is a U.S.-based specialty pharmaceutical company focused on developing and, if successful, commercializing therapies for neurologic diseases and other high-unmet-need indications. The company was incorporated in Delaware on February 9, 2015, and its headquarters are in Bay Harbor Islands, Florida, at 1111 Kane Concourse, Suite 301, in the Miami area. Avenue was founded by Fortress Biotech, Inc., and Fortress remains the controlling shareholder, which means Avenue should be viewed as a small, controlled biotech platform rather than a large independent pharmaceutical company. ([ir.avenuetx.com](https://ir.avenuetx.com/)) From a market perspective, ATXI is no longer listed on a major U.S. national exchange. In its latest annual filing, Avenue states that its common stock is not currently listed on a national securities exchange and is quoted on the OTC Pink Open Market under the symbol ATXI. For investors, that distinction matters: liquidity, institutional coverage, and market depth are typically much lower on OTC than on NYSE or Nasdaq. Although ATXI has historically been associated with Nasdaq, the company’s current disclosure is the operative reference point. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1644963/000143774926010359/atxi20251231_10k.htm)) Avenue’s business model is highly pipeline-driven and currently concentrated in a very limited number of assets. Historically, the company developed IV tramadol for postoperative acute pain. More recently, management has pivoted toward ATX-04, a clenbuterol-based program described as a selective beta-2 adrenergic agonist being developed for lysosomal storage diseases, with an initial focus on Pompe disease as an adjunct to enzyme replacement therapy. In February 2026, Avenue signed an exclusive worldwide license agreement with Duke University covering patents and know-how related to ATX-04. The deal included an upfront payment, potential development, regulatory and commercial milestone obligations, and a low single-digit royalty on future net sales. The company has also indicated that it intends to engage the FDA around a potential pivotal study design. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1644963/000143774926010359/atxi20251231_10k.htm)) Competitively, Avenue occupies the profile of a micro-cap clinical-stage biotech: limited revenues, no commercial products for sale, heavy dependence on capital markets, and binary value creation tied to clinical and regulatory outcomes. The latest filing explicitly notes substantial accumulated deficits and a going-concern risk, underscoring the financing pressure on the business. In November 2025, Avenue completed the sale of its Baergic Bio subsidiary to Axsome Therapeutics, further simplifying the portfolio and reinforcing its focus on ATX-04 and a narrow development strategy. Operationally, the company is largely U.S.-centric, with no meaningful commercial international footprint disclosed at this stage. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1644963/000143774926010359/atxi20251231_10k.htm)) For international equity investors, Avenue Therapeutics should be framed as a speculative U.S. biotech story with asymmetric upside linked to ATX-04 and significant execution, funding, and regulatory risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1644963/000143774926010359/atxi20251231_10k.htm))